Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease (PD) and multiple system atrophy (MSA). Scientists have found a way to distinguish ...
Multiple system atrophy (MSA) is a neurodegenerative disease with multiple debilitating symptoms. One of them is sleep disorders; however, owing to limited research, little is known about why only ...
Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with an ...
The Food and Drug Administration (FDA) has granted Fast Track designation to verdiperstat (BVH-3241; Biohaven) for the treatment of multiple system atrophy. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results